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Abstract
Human epidermal growth factor receptor-2 (HER2/ErbB-2) is a 
receptor tyrosine kinase involved in cell growth and differentiation and 
over-expressed in about 15-30% of breast cancers. Trastuzumab is 
an anti-HER2 monoclonal antibody that has significantly improved 
survival of patients with early and metastatic breast cancer (BC). 
However, 65% patients experience primary and secondary 
resistance. This article explores existing and emerging combination 
therapy for HER2 positive breast cancer, highlighting the success 
of trastuzumab in combination with another monoclonal antibody, 
pertuzumab and small molecule tyrosine kinase inhibitors lapatinib 
and neratinib. Recent studies have indicated that combination of 
trastuzumab, pertuzumab and lapatinib increases the 3-year overall 
survival from 90% to 95% in metastatic BC patients. The EPHOS-B 
trial has shown a remarkable shrinkage of the tumour when lapatinib 
is used before surgery and chemotherapy. Despite this success, 
pertuzumab has just been approved for use in the British National 
Health Service (NHS) while pertuzuamb, lapatinib and neratinib 
have been approved for European and American markets for a 
number of years. Lapatinib and neratinib are not available yet in UK. 
Strict assessment criteria on cost-benefits might limit the access to 
these drugs to British cancer patients.  
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Introduction 
Breast cancer (BC) is the second most common cancer in women 
worldwide [1]. Over-expression of the epidermal growth factor 
receptor encoded by the HER2/neu gene occurs in 15-25% of all BCs 
[1]. This phenotype is associated with a faster rate of cancer growth 
and an increased rate of metastasis, through aberrant signalling 
activating a variety of survival pathways including PI3K/Akt and 
RAS/MAPK [1]. The development of trastuzumab (Herceptin®), a 
humanised monoclonal antibody targeting the extracellular domain 
of HER2 protein, is one of the most significant advances in breast 
cancer therapy [1,2] (Figure 1).
Originally approved by the Food and Drug Administration 
(FDA) in the United States in 1998 for the treatment of metastatic 
HER2-positive BC, in combination with paclitaxel, trastuzumab 
recommendation has widened ever since (Table 1). In 2006 FDA 
approval was expanded to HER2-positive breast cancer patients in 
combination with chemotherapy and following primary treatment 
of early stage breast cancer. In 2008 trastuzumab was approved as 
monotherapy in the adjuvant setting and in 2014 it was approved 
as first-line treatment in HER2-positive metastatic BC [1,2]. This 
clearly indicates the clinical benefit of this drug. However, 70% of 
HER2-positive BC patients do not respond to trastuzumab due to 
de novo or acquired resistance [2-4]. Current research is focused on 
understanding mechanisms of trastuzumab resistance to develop new 
therapeutic strategies.
Mechanisms of resistance to trastuzumab
Several mechanisms of resistance to trastuzumab have been 
described [2,4] (Figure 2). The extracellular domain of HER2 is 
proteolytically cleaved by metalloproteinases, thus generating a 
mutated isoform of HER2, called p95HER2 that cannot bind to 
trastuzumab (Figure 2). p95HER2 is particularly oncogenic due 
to its constitutive kinase activation of downstream signaling, thus, 
inhibiting the effects of trastuzumab [5,6]. 
Another hypothesised mechanism of trastuzumab resistance 
is via disruption of the interaction between therapeutic antibodies 
and target protein. The membrane associated glycoprotein Mucin-4 
(MUC4) may mask the extracellular trastuzumab binding domain 
on HER2 thereby preventing trastuzumab from effectively binding 
(Figure 2). Nagy et al. used JIMT-1 trastuzumab resistant cell lines to 
demonstrate that the level of MUC4 is directly related to the ability 
of trastuzumab to bind, and that reduced levels of MUC4 increased 
the sensitivity of JIMT-1 cells to trastuzumab, whereas elevated 
expression of MUC4 masked HER2, resulting in steric hindrance 
between the drug and target protein [7]. 
As other members of the HER family are able to mediate oncogenic 
signalling pathways (PI3K/MAPK), the up-regulation of these proteins 
may provide a compensatory mechanism for the trastuzumab-
mediated inhibition of HER2 [1,2] for example, trastuzumab is 
unable to prevent HER3 dimerization [8]. Furthermore, HER2-HER3 
dimerization results in increased tyrosine phosphorylation of HER3 
leading to activation of PI3K pathway (Figure 2) [9]. Likewise ectopic 
expression of insulin like growth factor 1 receptor (IGF-1R) has been 
shown to induce resistance to trastuzumab [10]. Deficiency of the 
phosphatase and tensin homolog (PTEN) deleted from chromosome 
10 has also been associated with poor response to trastuzumab 
[11]. PTEN is a negative regulator of PI3K pathway, and thus, the 
deficiency of PTEN leads to constitutive activity of PI3K [11,12]. 
These mechanisms of resistance are currently the subject of intense 
research, but they have not yet led to a clinical benefit.
Combination regimens
An approach that has been extensively validated in the clinic 
is the combination of trastuzumab with another fully humanized 
monoclonal antibody, called pertuzumab, directed against the 
extracellular domain of HER2 [13]. The two antibodies work 
synergistically as the differences in their binding sites offer more 
complete blockade of HER2 (Figure 3). Indeed, upon pertuzumab 
binding, HER2 cannot dimerize either with another HER2 molecule or 
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A more recent study by Swain et al. demonstrated the efficacy of 
both trastuzumab and pertuzumab in combination with docetaxel 
[15]. In this trial 808 patients with previously untreated HER2-
positive metastatic BC were randomised between two arms, to receive 
pertuzumab plus the combination of trastuzumab and docetaxel 
chemotherapy vs. placebo plus the same combination of trastuzumab 
and docetaxel. Progression free survival (PFS) improved by 6.3 
an alternative HER partner [13]. Thus, the formation of HER2/HER3 
dimers, which is the most potent oncogenic receptor pair, is inhibited 
by pertuzumab [9]. In the neo-adjuvant setting the combination of 
pertuzumab, trastuzumab and docetaxel was shown to significantly 
improve pathological complete response (pCR) (45.8%) in early 
stage BC in comparison to trastuzumab and docetaxel (29%) without 
substantial differences in tolerability [14]. 
*Note: A) The HER2 dimerization (extracellular) causes a conformational change to the intracellular tyrosine kinase domain, thus, instigating a kinase 
cascade via PI3K/Akt and RAS/MAPK . B) Binding of trastuzumab to HER2 homodimers cause inhibition of the signalling cascade. 
Figure 1: A schematic representation of the signalling cascade of HER2.
*Note: Trastuzumab resistance can be achieved through a variety of mechanisms: the presence of MUC4 that masks the trastuzumab binding domain on 
HER2, the upregulation of HER family receptors to compensate trastuzumab-mediated inhibition of HER2, IGF-1R inducing resistance to trastuzumab and 
the deficiency of PTEN that leads to constitutive activity of PI3K pathway.
Figure 2: A schematic representations illustrating various mechanisms of trastuzumab resistance. 
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months in the group treated with pertuzumab combination (PFS=18.7 
months) in comparison to placebo (PFS=12.4 months). Moreover, 
the overall survival (OS) was significantly greater with pertuzumab 
combination than with the placebo (56.5 vs. 40.8 months). Toxicity 
was increased in the pertuzumab arm although the quality of life did 
not differ from the placebo arm [15]. 
In the phase IV NBRST trial () pertuzumab was administered to 
HER2 positive BC patients classified based on their molecular subtype 
(luminal A, luminal B, HER2-enriched and basal-like-and a normal-
like subtype), to determine which patients would clinically benefit 
from dual targeting and whether the HER2-enriched responded better 
than the others. The results show that the addition of pertuzumab 
led to an increased pCR rate for all HER2 positive patients except 
basal-type patients and the effect was most pronounced in the HER2 
enriched-type with 75.8% of patients achieving pCR [16].
In 2013, the FDA granted accelerated approval to pertuzumab for 
use in combination with trastuzumab and docetaxel, as neoadjuvant 
treatment of patients with HER2-positive breast cancer. This was 
approved in Europe in 2015 (Table 1).
Another promising strategy to overcome trastuzumab resistance 
is represented by small molecule dual tyrosine kinase inhibitors 
(SMDTKI). These molecules are able to compete with adenosine 
triphosphate (ATP) for the cytoplasmic catalytic kinase domain of 
HER2, preventing/reducing tyrosine phosphorylation, thus inhibiting 
downstream signalling [17] (Figure 3). Lapatinib is a reversible 
SMDTKI, which works by inhibiting the signalling cascade activated 
by auto-phosphorylation of HER2 homodynes [1,17-21]. Due to 
its ability to bind to the intracellular domain of HER2, lapatinib is 
capable of preventing signalling associated with p95HER2 and is 
suspected to increase trastuzumab-dependent antibody-dependent 
cell-mediated cytotoxicity (ADCC). Indeed, the accumulation of 
HER2 on the cell surface increases the overall binding of trastuzumab 
molecules to HER2 with the effect of attracting more immune cells to 
the tumour site.
Lapatinib has been successfully combined with a number of 
chemotherapy drugs including capecitabine [18] and paclitaxel 
[21]. The combination of paclitaxel and lapatinib versus paclitaxel 
and placebo has been shown to prolong the median OS from 20.5 
months to 27.8 months in metastatic BC patients [21]. Several studies 
are underway to evaluate the efficacy of the combination of lapatinib 
with trastuzumab and chemotherapy [19,20,21]. In a phase III study 
(Trial NCT00281658) in HER2 positive metastatic breast cancer 
patients, the combination of trastuzumab and lapatinib provided 
a significant overall survival advantage (4.5 months median), 
supporting the concept of dual HER2 blockade [19]. Further studies 
have indicated that combinations of lapatinib with trastuzumab 
represents a successful approach [21,23]. In the phase III NeoALTTO 
trial on early HER2 positive BC, the 3-year event-free survival was 
76% in the trastuzumab group, 78% in the lapatinib group and 84% 
in the combination group. The 3-year overall survival was 90% for 
trastuzumab, 93% for lapatinib and 95% for combination therapy 
Drug Date of approval UK 
(NICE)
Date of approval EU
(EMA)
















Approved for adjuvant treatment of early stage, node positive 
HER2-positive breast cancer, in combination with chemotherapy
- - January
2008
Approved for adjuvant treatment of early stage, node positive or 
node negative HER2-positive breast cancer
July
2014
Approved as first line treatment of advanced HER2-positive 
breast cancer










Accelerated approval in US for use in combination with docetaxel 
and trastuzamab for HER2-positve early stage, inflammatory or 
locally advanced breast cancer
Lapatanib - June 2008 Conditional 
marketing authorisation.
Full marketing authorisation 
February 2015
March 2007 Accelerated approval in US for HER2-postive, postmenopausal 
women with hormone-positive metastatic breast cancer and for 
whom hormone therapy is indicated in combination therapy for 
women already using capecitabine.
- - January 2010 Accelerated approval  in US in combination with letrozole for 
HER2-postive, postmenopausal  women with hormone-positive 
metastatic breast cancer and for whom hormone therapy is 
indicated
- - Updated approval 2013 - Updated approval in EU to be used in combination with 
trastuzumab for HER-2 positive, hormone receptor-negative (HR) 
metastatic disease that had progressed with prior combination 
therapy including trastuzumab.
Neratinib 2017
Will report on technology 
appraisal.
June 2016
Application submitted to EMA
July 2017 Approved in US for extended adjuvant breast cancer that 
previously has been treated with trastuzamab therapy
NICE - National Institute for Health and Care Excellence
EMA - European Medicines Agency
FDA- Food and Drug Admiration
Table 1: Evolution of drugs approval in UK, EU and US.
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[22]. Although the overall survival did not significantly differ between 
the groups, the study confirmed that those who achieved pCR after 
neoadjuvant therapy experienced longer overall survival than patients 
that did not reach pCR. In the phase III ALTTO trial, which studied 
the effects of lapatinib in an adjuvant setting, comparing trasutuzmab 
mono-therapy, lapatinib mono-therapy and the combination of 
trastuzumab and lapatinib, the results indicated a 16% reduction in 
disease-free survival (DFS) in the combination arm compared to 
trastuzumab alone but was not statistically significant. Moreover, 
lapatinib was associated with higher rates of toxicity and therefore 
its role in an adjuvant setting remains uncertain [Piccart-Gebhart, 
2016]. A recent meta-analysis which included seven clinical trials 
concluded that the combination of trastuzumab and lapatinib can 
improve pCR, PFS and OS without added toxicity in patients with 
HER2-positive BC. This might indicate that large-scale trials and 
statistical power are needed to fully evaluate the efficacy of dual 
blockade regimens [24]. 
In 2016 at the European Breast Cancer Conference, promising 
data highlighted the potential of the combination trastuzumab, 
pertuzumab and lapatinib. The data refer to a clinical trial still on-
going, the EPHOS-B, whereby lapatinib, in combination with 
trastuzumab and pertuzumab, was shown to shrink the tumour size 
before surgery or chemotherapy in just eleven days. These results 
indicate that there are patients that might be spared invasive surgery 
and toxic chemotherapy treatment. 
Recently, a phase II study, the PAMELA trial, was conducted on 
naive HER2 positive BC patients, classified based on their molecular 
subtype. The patients were treated with lapatinib and trastuzumab 
and underwent surgery 1-3 weeks after the last dose of treatment. 
The primary outcome of the study was to assess whether the HER2-
enriched subtype predict pCR at the time of surgery. The results 
showed that 41% of the patients with HER2-enriched subtype 
achieved pCR whereas only 10% of patients with non-HER2 enriched 
subtype achieved pCR at the time of surgery [25]. These data suggest 
that HER2-enriched subtype BC cancer patients are the most likely to 
benefit from dual blockade regimens. 
Lapatinib was approved by the FDA in 2010 in combination 
with letrozole for the treatment of postmenopausal women with 
hormone receptor and HER2-positive metastatic breast cancer. 
Then it was approved in Europe in 2013 to be used in combination 
with trastuzumab in women with HER2-positive hormone receptor 
negative metastatic breast cancer that has progressed on prior 
treatment with trastuzumab in combination with chemotherapy. 
Lapatinib is not available in the UK on the NHS, the British health 
service (Table 1).
Recent research has suggested acquired resistance to lapatinib; 
however this resistance is observed only when lapatinib is used in 
combination with chemotherapy rather than in combination with 
trastuzumab and pertuzumab [23]. A proposed mechanism of 
acquired resistance to lapatinib is thought to be a result of the up-
regulation of HER3 receptors. Lapatinib induces activation of the 
transcription factor FOXO3a, which stimulates the expression of 
HER3 [26]. 
As drug resistance is an important feature of reversible SMDTKIs 
there is a demand for more potent inhibitors, which offer the potential 
to sustain an antitumor environment. Neratinib is an irreversible 
pan-HER inhibitor (HER1, 2 and 4) which has shown promising 
responses in several trials [27]. The FDA recently approved neratinib 
for early HER2 positive breast cancer based on the data from the 
pivotal phase III ExteNET trial (FDA.GOV, 2017). In pre-clinical 
studies neratinib showed better responses than lapatinib, suggesting 
that neratinib could overcome both primary and acquired resistance 
to trastuzumab [28]. Neratinib binds to the ATP pocket domain of 
HER 1, 2 and 4, whereas, lapatanib only targets HER1 and HER2. 
The additional kinase inhibition may overcome the up regulation of 
other HER receptor signalling and this may account for the improved 
responses observed [27]. There are several trials currently underway 
to evaluate the clinical use of neratinib as treatment for HER2-positive 
BC: Trial NCT00915018 is comparing neratinib in combination with 
paclitaxel and trastuzumab against paclitaxel alone in patients with 
advanced HER2-positive BC. The efficacy of neratinib in comparison 
to trastuzumab was investigated in a first-line setting together with 
paclitaxel on recurrent and/or metastatic HER2-positive BC patients. 
The results showed that the addition of neratinib did not significantly 
improve the PFS of the patients compared to trastuzumab (12.9 
months in both arms) [29]. 
*Note: Trastuzumab and pertuzumab inihibit HER2 homodimerization via binding to HER2 extracellular domain. Lapatinib binds HER2 intracellular domain. 
Figure 3: A schematic illustrations of the mechanisms of trastuzumab, pertuzumab and lapatinib.
Citation: Patel S, Hayes N, Esposito MT (2017) Trastuzumab Resistance: What Are We Offering to Breast Cancer Patients? J Clin Exp Oncol 6:6.
• Page 5 of 6 •
doi: 10.4172/2324-9110.1000203
Volume 6 • Issue 6 • 1000203
A study (ExteNET trial) by Chan et al. evaluated the use of 
neratinib after chemotherapy and trastuzumab based adjuvant 
therapy in patients with HER2 positive BC. The results indicated 
that neratinib prolonged the 2-year invasive disease-free survival rate 
from 91.6% to 93.9%, and reduced the risk of recurrence by 33% [30]. 
However these results should be considered with caution because of 
the short follow-up time [30]. 
In the NSABP-FB-7 study conducted on advanced HER2 
positive BC patients, the effects of neratinib and/or trastuzumab 
plus doxorubicin and cyclophosphamide in a neoadjuvant setting 
demonstrated a pCR rate of 33% for neratinib, 38% for trastuzumab 
and 50% in the combination arm. This trial is still on-going.
However, as the tyrosine kinase structure is well preserved, the 
probability of multiple kinase ligand binding is high due to the non-
specific binding properties of small molecule therapies. Thus, more 
research must be conducted for targeted binding sites in order to 
produce beneficial outcomes. 
Despite the evidence and the results obtained with trastuzumab, 
pertuzumab, lapatinib and neratinib in clinical trials, British patients 
seem not to fully benefit from the scientific advancement in the 
cancer- drug discovery field. 
Trastuzumab was approved in the UK in 2002, after pressure 
from patients, 4 years after its approval in the States. Pertuzumab 
has just been approved for use in the NHS. In May 2016 NICE, the 
National Institute for Health and Clinical Excellence, a regulatory 
body that advises the British health service, did not recommend the 
use of pertuzumab to treat HER2-positive breast cancer based on the 
observation that there was uncertainty around how the responses to 
treatment seen in the clinical trials might translate into long term 
benefits for patients. The reason for this halt in adopting the new 
treatment seemed to lay on the ratio between cost and benefits. In 
November 2016 NICE approved pertuzumab after its manufacturer, 
Roche, agreed a discount on its price. Lapatinib and neratinib are not 
available yet in the UK.
Conclusions
The results of the clinical trials presented highlight the efficacy 
of combining trastuzumab with pertuzumab in breast cancer 
patients and show promising results when these two are combined 
with lapatinib. Trastuzumab represents the gold standard for HER2 
positive BC. Moreover, molecular subtyping of HER2 positive breast 
cancer patients has the potential to predict which patients may 
benefit the most from combinational regimens, to personalize the 
treatment as well as avoid unnecessary toxicity to those that may 
not benefit. The personalized treatment based on molecular subtype 
has not yet entered routine clinical practice. Approximately 11,500 
women die every year from breast cancer in the UK and resistance 
to current treatment is an increasingly important issue. NICE 
approved pertuzumab for HER2 positive BC only recently after 
agreeing a discount with Roche. This is also the route followed by 
other cancer drugs. In July 2016 NICE approved the tyrosine kinase 
inhibitor bosutinib for chronic myeloid leukaemia patients who 
have not responded to first and second line treatment by negotiating 
a discount with the manufacturer of the drug, Pfizer [31]. Prior to 
this move bosutinib was available to British patients only through the 
Cancer Drug Fund (CDF) due to its prohibitive price. The CDF was 
introduced in England in October 2010 to provide access to cancer 
treatments that are not routinely available on the NHS. After being 
closed in October 2015, the CDF opened again in April 2016 with 
37 indications on its lists. Bosutinib was the first drug on the list to 
be approved after the reappraisal. Pertuzumab was rejected in May 
and then approved in November after Roche submitted a further 
discount. Unfortunately lapatinib and neratinib are not on this list. It 
is unclear whether they will be approved for the British market.
The British government should take a step forward and negotiate a 
better price with the pharmaceutical industries [32]. NICE guidelines 
should be also reviewed in light of new pricing arrangements. It seems 
a paradox that British residents, that largely fund cancer research 
through a number of charities sponsoring some of the studies cited in 
this article, are excluded from the benefits of this research.
We need to rethink how new drugs are made available to patients.
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